RESUMEN
Bobble-head doll syndrome (BHDS) is a rare entity, characterized by antero-posterior head bobbing, which is of the type "yes-yes." Less frequently, having a head movement of the type "no-no" is described. We report an unusual case of an 80-year-old man with a cystic mass of the lamina quadrigemina, extending to the posterior fossa. We conclude that ventriculocystocisternotomy associated with a cystoperitoneal shunt is an effective treatment for a symptomatic giant arachnoid cyst in the lamina quadrigemina.
Asunto(s)
Quistes Aracnoideos/cirugía , Derivaciones del Líquido Cefalorraquídeo , Discinesias/cirugía , Endoscopía/métodos , Techo del Mesencéfalo/cirugía , Tercer Ventrículo/anomalías , Ventriculostomía/métodos , Anciano de 80 o más Años , Humanos , Masculino , Tercer Ventrículo/cirugía , Resultado del TratamientoRESUMEN
BACKGROUND: Parkinson's disease justifies the use of deep brain stimulation (DBS) in certain patients who suffer from this condition. We present mid-term and long-term post-surgical outcomes in a cohort of 60 patients, who underwent DBS in the Hospital de Especialidades at Centro Médico Nacional Siglo XXI, in Mexico City. METHODS: Patients underwent conventional stereotactic surgery with FrameLink software (Medtronics Inc). This technique consisted in the presurgical evaluation, the placement of stereotactic frame, imaging studies, preoperative planning procedure, microrecording, macrostimulation, as well as the placement of electrodes and generators in two phases. The variables were included in a data platform for Excel management. It was also included a variety of measurement instruments for data comparison. As a standard measure, it was used the Unified Parkinson Disease Rating Scale (UPDRS) before the surgery and at 3, 12, and 36 months. RESULTS: 60 patients underwent surgery: 41 men and 19 women, with an average age of 56.5 years (39-70). There were good results in the majority of patients with preoperative UPDRS and at 3, 12 and 36 months of 79.57, 66.85, 65.29 and 58.75, respectively (p < 0.0001). There were complications in nine patients (15 %) and they were managed in a conservative manner. CONCLUSIONS: Postsurgical outcomes were from good to excellent in the majority of patients. Complications were minimal and conservatively managed. We propose the use of this procedure in a selected group of Parkinson's patients.
Introducción: la enfermedad de Parkinson puede justificar un procedimiento quirúrgico que consiste en la estimulación cerebral profunda. Se presentan resultados a mediano y largo plazo de una cohorte de 60 pacientes del Hospital de Especialidades del Centro Médico Nacional Siglo XXI. Métodos: los pacientes fueron operados con una metodología estereotáctica convencional a través del protocolo FrameLink (Medtronics Inc.). La técnica consistió en la evaluación preoperatoria de los pacientes, la colocación de marco estereotáctico, la realización de estudios de imagen, la planeación preoperatoria, el microrregistro, la macroestimulación y la colocación de implantes, que estuvo conformada por electrodos y generador en dos fases. La escala unificada para la evaluación de la enfermedad de Parkinson (UPDRS) preoperatoria, a tres, 12, y 36 meses fue utilizada como medida estándar. Se analizaron los resultados y las complicaciones como variables de interés. Resultados: se operaron 60 pacientes (41 hombres y 19 mujeres), con edad promedio de 56.5 años (rango de 39-70). Se obtuvieron de buenos a excelentes resultados en la mayoría de los pacientes con UPDRS promedio en periodo preoperatorio, a 3, 12 y 36 meses de 79.57, 66.85, 65.29 y 58.75, respectivamente (p < 0.0001). Las complicaciones se presentaron en forma mínima (en nueve pacientes: 15 %) y fueron manejadas de forma conservadora. Conclusiones: hubo una mejoría progresiva en el UPDRS durante los 36 meses de seguimiento.
Asunto(s)
Estimulación Encefálica Profunda , Enfermedad de Parkinson/terapia , Adulto , Anciano , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Técnicas Estereotáxicas , Resultado del TratamientoRESUMEN
OBJECTIVE: To assess the frequency of postural and striatal deformities in patients with Parkinson's disease. PATIENTS AND METHODS: A total of 416 consecutive patients with Parkinson's disease were evaluated for musculoskeletal deformities using a standardized criteria. Data including disease history, motor complications and antiparkinsonic treatment were collected. RESULTS: The overall frequency of musculoskeletal deformities was 19.7%. Striatal deformities were the most frequent deformities (9.9%). Scoliosis was the deformity most frequently found. No cases with Pisa syndrome or antecollis were found. Striatal deformities were associated with a younger age at onset, more frequent use of levodopa, as well as higher levodopa equivalent daily dose. Postural deformities were associated with higher motor scores. CONCLUSION: Postural and striatal deformities are common in Parkinson's disease. Striatal deformities appear to be more related to dopaminergic treatment, while postural deformities are associated with the motor state.
Asunto(s)
Cuerpo Estriado/fisiopatología , Mano , Enfermedad de Parkinson/fisiopatología , Postura/fisiología , Adulto , Edad de Inicio , Anciano , Cuerpo Estriado/efectos de los fármacos , Femenino , Mano/fisiopatología , Humanos , Levodopa/uso terapéutico , Masculino , Persona de Mediana Edad , Enfermedad de Parkinson/tratamiento farmacológicoRESUMEN
OBJECTIVE: The aim of this study is to determine the usefulness of the University of Pennsylvania smell identification test (UPSIT), sniffin sticks (SS-16) and brief smell identification test (B-SIT) to assess smell identification in the Mexican population and its accuracy in discriminating subjects with Parkinson's disease (PD). METHODS: We included 199 nondemented PD subjects and 199 control subjects matched by gender. Smell identification was tested using the UPSIT and SS-16. Our group obtained B-SIT data from a previous report. RESULTS: The mean number of UPSIT items correctly identified by controls was 27.3±6; the PD group had a mean score of 19.4±6. UPSIT had a sensitivity of 82% with a specificity of 66% for a cut-off score of ≤25 for detection of PD. The mean number of SS-16 items correctly identified by controls was 10.3±2.2, while the PD group had 7.4±2.8 correct answers. For SS-16, sensitivity was 77.8% and specificity of 71.2% when using a cut-off value of ≤9. Lemon, turpentine and rose had an identification rate below the 25th percentile for all three tests. Odors with an identification rate above the 75th percentile include banana for all three tests, and gasoline, onion and chocolate for UPSIT and B-SIT. CONCLUSION: The sensitivity and specificity of the smell tests that were evaluated were lower in comparison to other published reports. Cultural biases and smell familiarity may influence the test results. The development of a true cross-culturally adapted smell identification test is warranted may improve test accuracy.
Asunto(s)
Cultura , Pruebas Neuropsicológicas , Trastornos del Olfato/diagnóstico , Enfermedad de Parkinson/fisiopatología , Olfato/fisiología , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , México , Persona de Mediana Edad , Trastornos del Olfato/etiología , Enfermedad de Parkinson/complicaciones , Sensibilidad y EspecificidadRESUMEN
OBJECTIVE: The aim of this study is to determine if the University of Pennsylvania's Smell Identification Test (UPSIT) is an accurate diagnostic tool for olfactory dysfunction in Parkinson's disease (PD). METHOD: We included 138 non-demented PD subjects and 175 control subjects matched by gender. Smell identification was tested using UPSIT. RESULTS: The mean number of UPSIT items correctly identified by controls was 27.52 ± 5.88; the mean score for PD subjects was 19.66 ± 6.08 (p=<0.001). UPSIT sensitivity was 79.7% with a specificity of 68.5% using a cut-off score of ≤ 25. The overall accuracy for the diagnosis of PD was of 75.3%. CONCLUSION: UPSIT accuracy and specificity were lower than what has been previously reported. Our data demonstrates that 17.5% of items of the UPSIT were not well identified by healthy controls. Further research of the identification of a truly cross-cultural test is warranted.
Asunto(s)
Trastornos del Olfato/diagnóstico , Enfermedad de Parkinson/diagnóstico , Olfato/fisiología , Anciano , Estudios de Casos y Controles , Femenino , Humanos , Masculino , México , Persona de Mediana Edad , Trastornos del Olfato/fisiopatología , Enfermedad de Parkinson/fisiopatología , Análisis de Regresión , Reproducibilidad de los Resultados , Factores de Riesgo , Sensibilidad y EspecificidadRESUMEN
Objective: The aim of this study is to determine if the University of Pennsylvania’s Smell Identification Test (UPSIT) is an accurate diagnostic tool for olfactory dysfunction in Parkinson’s disease (PD). Method: We included 138 non-demented PD subjects and 175 control subjects matched by gender. Smell identification was tested using UPSIT. Results: The mean number of UPSIT items correctly identified by controls was 27.52±5.88; the mean score for PD subjects was 19.66±6.08 (p=<0.001). UPSIT sensitivity was 79.7% with a specificity of 68.5% using a cut-off score of ≤25. The overall accuracy for the diagnosis of PD was of 75.3%. Conclusion: UPSIT accuracy and specificity were lower than what has been previously reported. Our data demonstrates that 17.5% of items of the UPSIT were not well identified by healthy controls. Further research of the identification of a truly cross-cultural test is warranted. .
Objetivo: O objetivo deste estudo é determinar se o University of Pennsylvania Smell Identification Test (UPSIT) é uma ferramenta diagnóstica útil para a caracterizar disfunção olfativa na doença de Parkinson (DP). Método: Foram incluídos 138 indivíduos não dementes assuntos PD e 175 indivíduos controle pareados por sexo. Identificação cheiro foi testada usando UPSIT. Resultados: O número médio de itens UPSIT corretamente identificados pelos controles foi de 27,52±5,88; para sujeitos com DP foi de 19,66±6,08 (p=<0,001). A sensibilidade do UPSIT foi de 79,7%, com especificidade de 68,5%, utilizando um ponto de corte de ≤25. A exatidão global para o diagnóstico de DP foi de 75,3%. Conclusão: A precisão e a especificidade do UPSIT foram menores do que o que foi relatado anteriormente. Nossos dados demonstram que 17,5% dos itens da UPSIT não foram adequadamente identificados pelos controles saudáveis. São necessárias outras pesquisas para a identificação de um teste verdadeiramente cross-cultural nessa área. .
Asunto(s)
Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Trastornos del Olfato/diagnóstico , Enfermedad de Parkinson/diagnóstico , Olfato/fisiología , Estudios de Casos y Controles , México , Trastornos del Olfato/fisiopatología , Enfermedad de Parkinson/fisiopatología , Análisis de Regresión , Reproducibilidad de los Resultados , Factores de Riesgo , Sensibilidad y EspecificidadRESUMEN
INTRODUCTION: The Mexican Registry of Parkinson´s disease (ReMePARK) is nested within a multicentric cohort aimed to describe motor, non-motor, and genetic determinants of Parkinson's disease in Mexican patients. MATERIAL AND METHODS: To date, clinical and demographic data from 1,083 subjects has been obtained. Here we present the demographic and clinical data of the current sample along with its comparison with international reports. RESULTS: A total of 607 male and 476 female subjects with Parkinson's disease were included. The mean age of the patients was 64.7 ± 12.9 years. The time from onset of symptoms to diagnosis was 2.4 ± 2.6 years. About 34% of subjects had only elementary education. Of the subjects, 54.4% were under treatment with dopamine agonists. CONCLUSION: Subjects with Parkinson's disease incorporated into ReMePARK are comparable with other international registries, with the exception of the years of formal education, time to diagnosis, and the use of dopamine agonists. The characterization of the Mexican population with Parkinson's disease will improve diagnosis and therapeutic management as well as define research efforts in this area. Finally, registry future directions are presented.
Asunto(s)
Enfermedad de Parkinson/diagnóstico , Femenino , Humanos , Masculino , México , Persona de Mediana Edad , Sistema de RegistrosRESUMEN
BACKGROUND AND AIMS: Parkinson's disease (PD) is the second most common chronic neurodegenerative disorder. PD is clinically characterized by a constellation of motor and nonmotor symptoms that may have a direct effect on daily activities as well as in the quality of life of the patient. Identifying the symptoms more closely associated with a poor quality of life is central on improving the medical care of the patient. We undertook this study to identify and describe the clinical and demographic factors that predict health-related quality of life among Mexican patients with PD. METHODS: One hundred seventy-seven patients with Parkinson's disease were included. Patients were evaluated using the following clinimetric instruments: motor subscale of the Unified Parkinson's disease rating scale, Hoehn and Yahr stage, Non-motor Symptoms Questionnaire, Parkinson's disease Questionnaire (PDQ-39) and the Mini Mental Status Examination. RESULTS: Multivariate analysis showed that the main factors associated with a poor quality of life were motor impairment (ß = 0.27, p <0.001) and the number of nonmotor symptoms (ß = 2.17, p <0.001). The main nonmotor domains impacting on the quality of life were depression/anxiety (ß = 6.36, p <0.001), cardiovascular (ß = 5.39, p = 0.001), memory (ß = 4.64, p <0.001) and miscellaneous (ß = 3.15, p = 0.001). CONCLUSIONS: Both motor and mainly nonmotor symptoms are negatively associated with health-related quality of life in patients with PD and should be appropriately attended in order to improve patient care.
Asunto(s)
Enfermedad de Parkinson/psicología , Calidad de Vida , Anciano , Femenino , Humanos , Masculino , México , Persona de Mediana Edad , Actividad Motora , Análisis Multivariante , Enfermedad de Parkinson/fisiopatología , Escalas de Valoración Psiquiátrica , Índice de Severidad de la Enfermedad , Encuestas y CuestionariosRESUMEN
Underweight and malnutrition are well documented in Parkinson's disease (PD), while overweight has been less reported. We carried out a cross-sectional study including 177 healthy controls and 177 PD patients attending a tertiary care center. We recorded weight and height for all participants. A statistically significant difference was found in body mass index (BMI) between controls and PD patients (29.1±5.4 versus 27.2±4.7, p<0.001). In the PD Group, two patients were underweight, 32.7% were within normal range, 46.9% had overweight, and 19.2% were obese. Overweight and normal weight were more prevalent in the PD Group (p=<0.01 and <0.001, respectively) when compared to controls. In conclusion, overweight/obesity are common among patients with PD, while underweight is almost negligible.
Asunto(s)
Índice de Masa Corporal , Sobrepeso/epidemiología , Enfermedad de Parkinson/epidemiología , Anciano , Antiparkinsonianos/administración & dosificación , Estudios de Casos y Controles , Dopaminérgicos/administración & dosificación , Discinesia Inducida por Medicamentos , Femenino , Humanos , Levodopa/administración & dosificación , Masculino , México/epidemiología , Persona de Mediana Edad , Obesidad/epidemiología , Enfermedad de Parkinson/tratamiento farmacológico , Prevalencia , Índice de Severidad de la Enfermedad , Delgadez/epidemiologíaRESUMEN
Underweight and malnutrition are well documented in Parkinson's disease (PD), while overweight has been less reported. We carried out a cross-sectional study including 177 healthy controls and 177 PD patients attending a tertiary care center. We recorded weight and height for all participants. A statistically significant difference was found in body mass index (BMI) between controls and PD patients (29.1±5.4 versus 27.2±4.7, p<0.001). In the PD Group, two patients were underweight, 32.7% were within normal range, 46.9% had overweight, and 19.2% were obese. Overweight and normal weight were more prevalent in the PD Group (p=<0.01 and <0.001, respectively) when compared to controls. In conclusion, overweight/obesity are common among patients with PD, while underweight is almost negligible.
Baixo peso e desnutrição são muito documentadas na doença de Parkinson (DP), enquanto que o excesso de peso tem sido menos relatado. Foi realizado um estudo transversal com 177 controles saudáveis e 177 pacientes com DP que frequentavam um centro terciário. O peso e a altura de todos os participantes foram arquivados. Uma diferença estatisticamente significativa no índice de massa corporal (IMC) foi encontrada entre controles e pacientes com DP (29,1±5,4 versus 27,2±4,7, p<0,001). No Grupo DP, dois pacientes estavam abaixo do peso, 32,7% estavam dentro do intervalo normal, 46,9% apresentavam sobrepeso e 19,2% eram obesos. Peso normal e excesso de peso foram mais prevalentes no Grupo DP (p=<0,01 e <0,001, respectivamente) em relação aos controles. Em conclusão, o sobrepeso/obesidade são comuns entre os pacientes com DP, enquanto baixo peso nessa população é quase insignificante.
Asunto(s)
Anciano , Femenino , Humanos , Persona de Mediana Edad , Índice de Masa Corporal , Sobrepeso/epidemiología , Enfermedad de Parkinson/epidemiología , Antiparkinsonianos/administración & dosificación , Estudios de Casos y Controles , Discinesia Inducida por Medicamentos , Dopaminérgicos/administración & dosificación , Levodopa/administración & dosificación , México/epidemiología , Obesidad/epidemiología , Prevalencia , Enfermedad de Parkinson/tratamiento farmacológico , Índice de Severidad de la Enfermedad , Delgadez/epidemiologíaRESUMEN
INTRODUCTION: Parkinson's disease is a neurodegenerative disorder characterized by bradykinesia, resting tremor and rigidity. Pathologically, Parkinson's disease is defined by the presence of Lewy bodies, which result from the aggregation of alpha-synuclein. Braak, et al. have proposed that the aggregation of alpha-synuclein pathology in Parkinson's disease begins in the medulla oblongata and progresses predictably, reaching the substantia nigra in the midbrain after affecting the brain stem. Apart from the motor symptoms of the disease, non-motor symptoms may precede the evoked potentials, and these include cognitive dysfunction, psychiatric disorder, sleep disorders and autonomic dysfunction. OBJECTIVE: To describe and discuss the non-motor symptoms and diagnostic tests and procedures which may provide a pre-motor diagnosis of Parkinson's disease. CONCLUSIONS: Non-motor symptoms are now accepted as an integral part of the clinical spectrum of Parkinson's disease and there is evidence to suggest that olfactory dysfunction and sleep disturbances may occur before motor signs. The presence of various non-motor symptoms in conjunction with imaging studies has the potential to detect patients with Parkinson's disease in the pre-motor phase. Nevertheless, a larger number of studies are required, in particular cohort design of subjects in risk.